Effecty LLC (“Effecty”) operates this website and the membership platform. Effecty LLC does not provide medical services. Effecty LLC connects you with healthcare providers licensed in your state who can provide medical weight loss services for you.

Please note that Compounded Semaglutide is not FDA approved. Compounded medications are compounded in an FDA compliant pharmacy.

The information found on this website is provided for educational and informational purposes only and does not constitute providing medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician, which can include meeting with a licensed healthcare provider through the Effecty online platform.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Effecty website. Neither Effecty nor any contributor to this website, makes any representations, express or implied, with respect to the information provided herein or to its use.

The FDA has not evaluated or approved any statements made on this website and the FDA has not approved compounded medications to diagnose, treat, cure or prevent any disease or medical condition.

GLP-1 receptor agonists – including semaglutide and tirzepatide – have been prescribed (on and off label) for weight management, including obesity, along with a reduced caloric diet and increased physical activity. Take precaution with and read all warnings concerning GLP-1 medications as they may cause serious side effects.

Important Safety Information for Semaglutide and Tirzepatide Medications

WARNING: RISK OF THYROID C-CELL TUMORS

• In rodents, GLP-1 receptor agonist medications such as semaglutide and tirzepatide cause dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether these medications cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
• Semaglutide and Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Symptoms of thyroid tumors include a mass in the neck, dysphagia, dyspnea, persistent hoarseness).

Warnings and Precautions

• Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
• Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. If you have a history of pancreatitis, tell your Effecty healthcare provider before starting treatment.
• Acute Gallbladder Disease: Treatment with GLP-1 receptor agonists, including semaglutide, was associated with an increased occurrence of cholelithiasis and cholecystitis.
• Hypoglycemia: GLP-1 receptor agonists lower blood glucose and can cause hypoglycemia. In individuals with type 2 diabetes, hypoglycemia is reported more often. Patients with type 2 diabetes taking a GLP-1 receptor agonist with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia and should carefully monitor blood glucose.
• Acute Kidney Injury: There have been reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion.
• Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists.
• Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Diabetic retinopathy is a risk in patients with type 2 diabetes taking GLP-1 receptor agonists. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
• Heart Rate Increase: Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in adult patients taking GLP-1 receptor agonists compared to placebo in clinical trials.
• Suicidal Behavior and Ideation: Suicidal behavior and ideation have been reported in clinical trials with other weight management products.
• Changes in Bowel Habits and Gastroparesis: Some patients report long term changes in bowel habits including chronic diarrhea or constipation as well as gastroparesis after use of GLP-1 receptor agonists.
• Changes in Face. Some patients also report an unusually thin, drawn or saggy look to their facial features due to rapid weight loss.
• Additional Risks and Long Term Impacts. Not all risks and long term effects of taking semaglutide and tirzepatide medications are currently known, and there may be other side effects and risks that are learned later or that are never fully confirmed.

Most Common Adverse Reactions

• Most common adverse reactions (incidence ≥5%) are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis

Drug Interactions

• The addition of GLP-1 receptor agonists in patients treated with insulin has not been evaluated.
• You should not use multiple GLP-1 receptor agonist medications at the same time.
• GLP-1 receptor agonists cause a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications you are also taking.
• The safety and effectiveness of GLP-1 receptor agonist medications in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

Use in Specific Populations

• Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue all GLP-1 receptor agonist medications immediately.  Discontinue all GLP-1 receptor agonist medications  at least 2 months before a planned pregnancy.

‍